摘要
目的:探讨富血小板血浆(PRP)联合点阵铒激光治疗面部痤疮瘢痕的临床效果。方法:选取2018年7月-2019年3月于本院整形美容科门诊就诊的28例面部痤疮瘢痕患者为研究对象,将其面部左侧作为对照组,右侧作为观察组。对照组采用重组人表皮生长因子联合点阵铒激光治疗,观察组则采用PRP联合点阵铒激光治疗。比较两组治疗总有效率、治疗前后VISIA评分、结痂、痂皮全部脱落时间及主观满意度。结果:观察组治疗总有效率明显高于对照组(P<0.05);观察组结痂及痂皮全部脱落时间均明显短于对照组(P<0.05);治疗后观察组纹理及毛孔VISIA评分均明显高于对照组(P<0.05)。观察组主观满意度优于对照组(P<0.05)。结论:PRP联合点阵铒激光治疗面部痤疮瘢痕临床效果较好,可显著提升的VISIA评分,更受患者认可。
Objective:To investigate the clinical effect of platelet-rich plasma(PRP)combined with lattice erbium laser in the treatment of patients with acne scars of face.Method:A total of 28 patients with acne scars of face in plastic and aesthetic surgery department of our hospital from July 2018 to March 2019 were selected as the research object.The left side of their face as the control group and the right side as the observation group.The control group was treated with recombinant human epidermal growth factor combined with lattice erbium laser,and the observation group were treated with PRP combined with lattice erbium laser.The total effective rate of treatment,VISIA score before and after treatment,scab formation,scab all peeling time and subjective satisfaction of two groups were compared.Result:The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The time of scab formation and scab all peeling in the observation group were significantly lower than those in the control group(P<0.05).After treatment,VISIA scores of texture and pore in the observation group were significantly higher than those in the control group(P<0.05).The subjective satisfaction of the observation group was better than that of the control group(P<0.05).Conclusion:The clinical effect of PRP combined with lattice erbium laser in the treatment of patients with acne scars of face is better,it can significantly improve the VISIA score and more recognized by patients.
作者
何艳屏
刘丽忠
徐昆明
江艳
HE Yanping;LIU Lizhong;XU Kunming;JIANG Yan(The Sixth Affiliated Hospital of Guangzhou Medical University(Qingyuan People’s Hospital),Qingyuan 511500,China;不详)
出处
《中国医学创新》
CAS
2020年第11期150-153,共4页
Medical Innovation of China
基金
广东省医学科学技术研究基金项目(B2017027)。
